American Association for Cancer Research Inc
+3
1538-7445
Monthly
0008-5472
1941
2154409300
United States
English
YES
pubsales@aacr.org
Cancer Research publishes impactful original studies, reviews, and opinion pieces of high significance to the broad cancer research community. Cancer Research seeks manuscripts that offer conceptual or technological advances leading to basic and translational insights into cancer biology. Manuscripts that focus on convergence science, the bridging of two or more distinct areas of cancer research, are of particular interest. The main scope of the journal is captured in its primary subsections: Cancer Biology Cancer Immunology Cancer Metabolism and Molecular Mechanisms Therapeutic Development and Chemical Biology Translational Cancer Biology Cancer Landscapes Computational Cancer Biology and Technology Convergence Science Manuscripts containing findings that significantly move the field of cancer research forward. A potentially generalizable, broadly impactful conclusion, or an incisive rationale that could interest a broad audience. Results that have not been previously published in another tumor, cell line, or organoid model. Studies that include a clearly written title and abstract that communicate the study's impact to non-experts. Development or demonstration of a technological method that will greatly facilitate one or more areas of cancer research; such studies must demonstrate the potential of the approach by providing new biological insights to be considered. Studies with a high level of rigor and reproducibility of the methodologic approach at the time of submission: Multiple models Inclusion of age/sex as a variable Orthogonal approaches to support a hypothesis Proper controls Current techniques
Anticancer drugs that directly target Signal Transducer and Activator of Transcription (Stat)3 have remained elusive. We present azetidine-based small molecules as a new class of potent Stat...
Background: ALK rearrangements occur in 3-6% of patients (pts) with lung adenocarcinoma. Lorlatinib, is a novel third generation ALK tyrosine kinase inhibitor (TKI) with proven efficacy for ...
OJSCloud offers a complete, free setup to get you publishing.
Start Your Free Journal!